TB500: Molecular Structure

Molecular Structure Overview#

TB500, the synthetic form of Thymosin Beta-4 (Tβ4), is a 43-amino acid peptide with the molecular formula C212H350N56O78S and a molecular weight of 4963.44 Daltons. The peptide is N-terminally acetylated, a post-translational modification that occurs naturally and is essential for its biological activity. The CAS number for Thymosin Beta-4 is 77591-33-4. The complete amino acid sequence in one-letter code is Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES.

Thymosin Beta-4 was first isolated and characterized from calf thymus extracts in the early 1980s by Low and Goldstein, who determined its complete amino acid sequence. The protein belongs to the beta-thymosin family, a group of 15 highly conserved small acidic peptides (pI approximately 5.1) that share a characteristic central LKKTET actin-binding motif. Among the beta-thymosins, Tβ4 is the most abundant member in mammalian tissues, with intracellular concentrations reaching 0.1-0.5 mM in some cell types.

Amino Acid Composition and Sequence Analysis#

The full three-letter amino acid sequence of TB500 is:

Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser

The sequence is notable for several features:

• High charge density: The peptide contains 8 glutamate (E), 6 lysine (K), and 2 aspartate (D) residues, giving it a net negative charge at physiological pH and contributing to its high water solubility
• Single methionine: Met-6 is the only sulfur-containing residue and represents a potential oxidation site that can affect biological activity
• LKKTET motif (residues 17-22): This hexapeptide is the minimal actin-binding sequence and is conserved across all beta-thymosins
• AGES C-terminal tetrapeptide (residues 40-43): Recent research has identified this region as important for cardioprotective activity
• Proline residues: Pro-4, Pro-28, and Pro-30 introduce kinks in the peptide backbone that contribute to its extended conformation

The amino acid composition is enriched in glutamic acid (18.6%), lysine (14.0%), and threonine (9.3%), while hydrophobic residues are relatively sparse. This composition produces a highly hydrophilic peptide with limited secondary structure in its free state.

Three-Dimensional Structure#

Free Peptide Conformation#

In aqueous solution, free Thymosin Beta-4 is largely unstructured and behaves as an intrinsically disordered protein (IDP). Nuclear magnetic resonance (NMR) studies have shown that the peptide adopts a random coil conformation with only transient helical propensity in the N-terminal region (approximately residues 5-16). This conformational flexibility is characteristic of WH2 (WASP homology 2) domain proteins, which undergo disorder-to-order transitions upon binding to their targets.

Actin-Bound Conformation#

The crystal structure of the Tβ4-actin complex (PDB ID: 1T5J) revealed that Thymosin Beta-4 undergoes dramatic conformational changes upon binding to G-actin. The bound conformation consists of:

1. N-terminal alpha-helix (residues 5-16): This amphipathic helix packs against the hydrophobic cleft between subdomains 1 and 3 of actin, in a manner similar to other WH2 domain proteins
2. Central connecting region (residues 17-24): The LKKTET-containing loop crosses the actin surface and positions the C-terminal portion for barbed-end capping
3. C-terminal extended strand (residues 25-40): This region extends across the top of actin, effectively capping the barbed end and preventing filament elongation

The binding interface buries approximately 2,800 square angstroms of surface area, with the N-terminal helix and central LKKTET motif contributing the majority of binding energy. The Kd for the Tβ4-actin interaction is approximately 0.5-2.0 micromolar, which is appropriate for a dynamic buffering system.

Physical and Chemical Properties#

Solubility#

TB500 is freely soluble in water and aqueous buffers due to its high proportion of charged residues and hydrophilic character. The peptide dissolves readily at concentrations exceeding 10 mg/mL in physiological saline or phosphate-buffered saline (PBS). This excellent water solubility facilitates both injectable and topical formulations without the need for organic co-solvents.

Stability Considerations#

The primary stability concern for TB500 is oxidation of the methionine residue at position 6 (Met-6). Oxidation of Met-6 to methionine sulfoxide reduces the peptide's affinity for G-actin and may compromise biological activity. This oxidation can be accelerated by exposure to light, elevated temperatures, or the presence of oxidizing agents.

Lyophilized TB500 is highly stable when stored at -20 degrees Celsius under desiccated conditions, retaining activity for years. Reconstituted solutions are less stable and should be refrigerated at 2-8 degrees Celsius. The addition of antioxidants (such as methionine or ascorbic acid) to reconstituted solutions can help prevent Met-6 oxidation. Repeated freeze-thaw cycles should be avoided, as they can promote aggregation and degradation.

Isoelectric Point and Charge#

The calculated isoelectric point (pI) of Thymosin Beta-4 is approximately 5.1, meaning the peptide carries a net negative charge at physiological pH (7.4). The theoretical charge at pH 7.4 is approximately -5.0, calculated from the 10 acidic residues (8 Glu + 2 Asp) minus the 6 basic residues (6 Lys) plus the acetylated N-terminus.

Pharmacokinetic Properties#

Absorption and Distribution#

Following intravenous administration in healthy human volunteers, synthetic Thymosin Beta-4 demonstrated dose-proportional pharmacokinetics across doses of 42 to 1260 mg. The volume of distribution exceeded total body water, suggesting tissue distribution beyond the vascular compartment. Endogenous Tβ4 is present in human serum at concentrations of approximately 12-18 ng/mL, with significantly higher concentrations in wound fluid and sites of tissue injury.

Metabolism and Elimination#

Thymosin Beta-4 is metabolized by cellular peptidases and aminopeptidases. The most pharmacologically significant metabolite is the N-terminal tetrapeptide Ac-SDKP (also known as seraspenide or goralatide), which is generated by the enzyme meprin-alpha. Ac-SDKP is itself a bioactive peptide with anti-fibrotic and hematopoietic stem cell regulatory properties. It is degraded by angiotensin-converting enzyme (ACE), and plasma levels of Ac-SDKP are elevated in patients receiving ACE inhibitor therapy.

The elimination half-life of intravenously administered Tβ4 is approximately 2 hours at lower doses but increases at higher doses, suggesting some degree of saturable elimination. Complete pharmacokinetic characterization, including bioavailability after subcutaneous or intramuscular injection, has not been published for humans.

Bioavailability by Route#

• Intravenous: 100% bioavailability (by definition); studied at 42-1260 mg in phase I trials
• Subcutaneous: Bioavailability not formally determined in humans; commonly used in research protocols with assumed good absorption given the peptide's small size and high solubility
• Topical (ophthalmic): Sufficient corneal penetration demonstrated for therapeutic effect in clinical trials using 0.1% solutions (RGN-259)
• Intraperitoneal: Used in animal studies; demonstrated systemic efficacy in wound healing and cardiac models

Key Functional Domains#

Relationship to TB-500 Fragment#

It is important to distinguish between full-length Thymosin Beta-4 (43 amino acids, MW 4963 Da) and the synthetic fragment commonly marketed as TB-500 (Ac-LKKTETQ, 7 amino acids, MW approximately 889 Da). The fragment corresponds to residues 17-23 of the full-length peptide and contains the core actin-binding and angiogenic domain. While this fragment retains some biological activities, particularly angiogenic and cell migratory effects, it lacks the full complement of binding surfaces present in the complete protein. Research studies typically use the full-length Thymosin Beta-4 peptide, and clinical trials have exclusively employed the full-length form.

Analytical Methods#

Thymosin Beta-4 is typically quantified using ELISA (enzyme-linked immunosorbent assay) for biological samples or HPLC (high-performance liquid chromatography) and LC-MS/MS (liquid chromatography-tandem mass spectrometry) for pharmaceutical quality control. The acetylated N-terminus and unique amino acid sequence provide diagnostic fragmentation patterns in mass spectrometry that allow for unambiguous identification and quantification even in complex biological matrices.

Related Reading#

• TB500 overview and research guide
• Peptides similar to TB500
• TB500 research evidence